Q, I have done some research after reading your post. An EASL 2012 slide clearly stated a 10 subject ELECTRON arm achieved 100% of SVR12 against HCV GT2/3. The arm was also treating for 8 weeks.
This 10 patient arm could be distinct from the arm for which they reported today. Either one is very wrong. They did not explain this discrepancy in today's report.
Today's report is closer to the truth because they are abandoning the 8 wk treatment regimen in favor of a 12 wk regimen for the GT2/3 Phase III. I also found a good amount of relapses between EOT and Week 4 and between Week 4 and Week 12 by comparing the AASLD abstract and today's report.